# Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

> **NCT05745857** · PHASE2 · RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 25 (estimated)

## Conditions studied

- Barrett's Esophagus Without Dysplasia
- Barrett Oesophagitis With Dysplasia
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Avastin
- **DRUG:** Erbitux
- **DEVICE:** Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy

## Key facts

- **NCT ID:** NCT05745857
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-15
- **Primary completion:** 2026-05
- **Final completion:** 2026-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05745857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05745857, "Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05745857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*